Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 01, 2024 | July 01, 2024 |
| Spark Therapeutics, Inc.ONCE · Entity 153045 | Chief Operating Officer | April 20, 2018 | April 24, 2018 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 01, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 · Expires 2034-07-01 | Direct | 660,000 |
Reported balance
After 2024-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 660,000 · Balance 660,000 F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Spark Therapeutics, Inc.
Report date April 20, 2018 · Filed April 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-04-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-20 · Exercise / conversion · Acquired 6,723 · Balance 6,723 Row 2 · 2018-04-20 · Sale · Disposed 6,723 · Balance 0 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.74 · Expires 2026-11-30 | Direct | 120,000 |
Reported balance
After 2018-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-20 · Exercise / conversion · Disposed 6,723 · Balance 120,000 F2: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.
F2: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,306 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 5,306 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001691218-26-000002 · wk-form4_1781641202.xml · derivative · entry 2 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001691218-26-000002 · wk-form4_1781641202.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,306 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001691218-25-000003 · wk-form4_1750111667.xml · derivative · entry 2 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001691218-25-000003 · wk-form4_1750111667.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,041 F1 · acquired: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 22:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 16,760 | $0.00 Strike: $76.06 | $0.00 |
DisclosureSEC source: 0001649094-24-000031 · wk-form4_1720044761.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,760 Underlying: Common Stock · 16,760 shares Expires 2034-07-01 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on July 2, 2025 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 21:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 660,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-24-076891 · tm2418639-3_4seq1.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,000 Underlying: Ordinary Shares · 660,000 shares Expires 2034-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:04 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 500,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001104659-23-077670 · tm2320409-6_4seq1.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares · 500,000 shares Expires 2033-07-03 F1 · derivative.exercise_price: The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 21:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 500,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-22-076898 · tm2220260-5_4seq1.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares · 500,000 shares Expires 2032-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:03 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 379,788 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001104659-21-088971 · tm2121284-5_4seq1.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,788 Underlying: Ordinary Shares · 379,788 shares Expires 2031-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 01, 2020 Filed Jul 1, 2020 21:09 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 196,186 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001104659-20-079788 · a4.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,186 Underlying: Ordinary Shares · 196,186 shares Expires 2030-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 240,541 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001104659-19-039324 · a4.xml · derivative · entry 1 Furey John · CIK 0001691218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,541 Underlying: Ordinary Shares · 240,541 shares Expires 2029-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,723 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001609351-18-000038 · wf-form4_152460181304900.xml · derivative · entry 3 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 6,723 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 6,723 | $82.50 | $554,647.50 |
DisclosureSEC source: 0001609351-18-000038 · wf-form4_152460181304900.xml · nonDerivative · entry 2 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 6,723 | $49.74 | $334,402.02 |
DisclosureSEC source: 0001609351-18-000038 · wf-form4_152460181304900.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · derivative · entry 6 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,723 Underlying: Common Stock · 11,000 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 11,000 | $82.53 | $907,830.00 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · nonDerivative · entry 4 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.68, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 11,000 | $49.74 | $547,140.00 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · nonDerivative · entry 3 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,277 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · derivative · entry 5 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,723 Underlying: Common Stock · 2,277 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 2,277 | $82.50 | $187,852.50 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · nonDerivative · entry 2 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:23 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 2,277 | $49.74 | $113,257.98 |
DisclosureSEC source: 0001609351-18-000032 · wf-form4_152416939151242.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 21:52 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001609351-18-000030 · wf-form4_152391552866539.xml · derivative · entry 3 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 20,000 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 21:52 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 20,000 | $77.51 | $1,550,200.00 |
DisclosureSEC source: 0001609351-18-000030 · wf-form4_152391552866539.xml · nonDerivative · entry 2 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $77.56, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 21:52 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 20,000 | $49.74 | $994,800.00 |
DisclosureSEC source: 0001609351-18-000030 · wf-form4_152391552866539.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000013 · wf-form4_151666588407746.xml · derivative · entry 2 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:04 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0001609351-18-000013 · wf-form4_151666588407746.xml · derivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: 25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| December 11, 2017 Filed Jan 23, 2018 00:03 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 18 | $46.33 | $833.94 |
DisclosureSEC source: 0001609351-18-000009 · wf-form4_151666576955298.xml · nonDerivative · entry 2 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By mother-in-law Disclosed balance after: 0 F1 · balance_after: Reflects transactions occurring in a brokerage account managed by an investment advisor who maintained discretionary authority over the account. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 08, 2017 Filed Jan 23, 2018 00:03 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | PurchaseCommon Stock | 18 | $73.48 | $1,322.64 |
DisclosureSEC source: 0001609351-18-000009 · wf-form4_151666576955298.xml · nonDerivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By mother-in-law Disclosed balance after: 18 F1 · balance_after: Reflects transactions occurring in a brokerage account managed by an investment advisor who maintained discretionary authority over the account. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:41 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001609351-16-000115 · wf-form4_148097409600576.xml · derivative · entry 1 Furey John · CIK 0001691218 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2026-11-30 F1 · derivative.exercise_date: 25% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.